These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 14978952

  • 21. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
    Rosenthal SA, Bae K, Pienta KJ, Sobczak ML, Asbell SO, Rajan R, Kerlin KJ, Michalski JM, Sandler HM, Radiation Therapy Oncology Group Trial 9902.
    Int J Radiat Oncol Biol Phys; 2009 Mar 01; 73(3):672-8. PubMed ID: 18990504
    [Abstract] [Full Text] [Related]

  • 22. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
    Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAleer C.
    J Clin Oncol; 1997 Sep 01; 15(9):3156-63. PubMed ID: 9294479
    [Abstract] [Full Text] [Related]

  • 23. [Hormonal chemotherapy for hormone-refractory prostate cancer].
    Nishimura K, Nakai Y, Shimizu K, Tokizane T, Arai Y, Inoue H, Takaha N, Nonomura N, Okuyama A, Kamoi K, Ukimura O, Miki T, Koide T, Ichikawa Y, Nishimura K, Sugao H, Yamaguchi S, Takatera H, Uchida K, Miura H.
    Hinyokika Kiyo; 2002 Nov 01; 48(11):713-8. PubMed ID: 12512147
    [Abstract] [Full Text] [Related]

  • 24. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
    Borghaei H, Millenson M, Schilder R, Alden M, Rogatko A, Wang H, Padavic-Shaller K, Smith MR.
    Cancer; 2004 Nov 01; 101(9):2034-41. PubMed ID: 15455357
    [Abstract] [Full Text] [Related]

  • 25. Paclitaxel in the treatment of hormone-refractory prostate cancer.
    Smith DC, Pienta KJ.
    Semin Oncol; 1999 Feb 01; 26(1 Suppl 2):109-11. PubMed ID: 10190791
    [Abstract] [Full Text] [Related]

  • 26. [Progress in oral anti-cancer drug therapy for urological cancer].
    Tsukamoto S, Akaza H.
    Gan To Kagaku Ryoho; 1999 Feb 01; 26(3):308-14. PubMed ID: 10065093
    [Abstract] [Full Text] [Related]

  • 27. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
    Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE.
    J Clin Oncol; 1994 Oct 01; 12(10):2005-12. PubMed ID: 7523606
    [Abstract] [Full Text] [Related]

  • 28. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
    Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V.
    Ann Oncol; 1999 Jan 01; 10(1):33-8. PubMed ID: 10076719
    [Abstract] [Full Text] [Related]

  • 29. [Effect of estramustine phosphate on hormone refractory prostate cancer].
    Tanaka M, Shiomi K, Hamano S, Suzuki N, Igarashi T, Murakami S, Shimazaki J.
    Hinyokika Kiyo; 1997 Mar 01; 43(3):245-50. PubMed ID: 9127765
    [Abstract] [Full Text] [Related]

  • 30. Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer.
    Segawa T, Kamoto T, Kinoshita H, Kunishima Y, Yoshimura K, Ito A, Takahashi T, Higashi S, Nakamura E, Nishiyama H, Ito N, Yamamoto S, Habuchi T, Ogawa O.
    Int J Clin Oncol; 2005 Oct 01; 10(5):333-7. PubMed ID: 16247660
    [Abstract] [Full Text] [Related]

  • 31. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer.
    Noguchi M, Itoh K, Suekane S, Morinaga A, Sukehiro A, Suetsugu N, Katagiri K, Yamada A, Noda S.
    Prostate; 2004 Jun 15; 60(1):32-45. PubMed ID: 15129427
    [Abstract] [Full Text] [Related]

  • 32. Combination therapy with VP16 and ethinylestradiol for hormone-refractory prostate cancer: good response with tolerability.
    Azuma H, Inamoto T, Takahara K, Ibuki N, Koyama K, Utimoto S, Fujisue Y, Uehara H, Komura K, Nomi H, Ubai T, Katsuoka Y.
    Anticancer Res; 2010 Sep 15; 30(9):3737-45. PubMed ID: 20944163
    [Abstract] [Full Text] [Related]

  • 33. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
    Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE.
    J Natl Cancer Inst; 2007 Nov 07; 99(21):1613-22. PubMed ID: 17971530
    [Abstract] [Full Text] [Related]

  • 34. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).
    Nicolini A, Mancini P, Ferrari P, Anselmi L, Tartarelli G, Bonazzi V, Carpi A, Giardino R.
    Biomed Pharmacother; 2004 Oct 07; 58(8):447-50. PubMed ID: 15464874
    [Abstract] [Full Text] [Related]

  • 35. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ, Hernandez-McClain J, Henary H.
    Am J Clin Oncol; 2008 Dec 07; 31(6):532-8. PubMed ID: 19060583
    [Abstract] [Full Text] [Related]

  • 36. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
    Kelly WK, Halabi S, Elfiky A, Ou SS, Bogart J, Zelefsky M, Small E, Cancer Leukemia Group B.
    Cancer; 2008 Dec 01; 113(11):3137-45. PubMed ID: 18989865
    [Abstract] [Full Text] [Related]

  • 37. Weekly paclitaxel plus estramustine combination therapy in hormone-refractory prostate cancer: a pilot study.
    Kuruma H, Fujita T, Shitara T, Egawa S, Yokoyama E, Baba S.
    Int J Urol; 2003 Sep 01; 10(9):470-5. PubMed ID: 12941125
    [Abstract] [Full Text] [Related]

  • 38. [The role of etoposide therapy in urogenital cancer].
    Kawai K, Akaza H.
    Gan To Kagaku Ryoho; 1996 Dec 01; 23(14):1929-35. PubMed ID: 8978800
    [Abstract] [Full Text] [Related]

  • 39. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
    Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ.
    J Clin Oncol; 1999 Jun 01; 17(6):1664-71. PubMed ID: 10561202
    [Abstract] [Full Text] [Related]

  • 40. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.
    Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B.
    J Clin Oncol; 1999 Oct 01; 17(10):3160-6. PubMed ID: 10506613
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.